Holbeck, Susan L.

The National Cancer Institute ALMANAC: a comprehensive screening resource for the detection of anticancer drug pairs with enhanced therapeutic activity

Holbeck, S. L., Camalier, R., Crowell, J. A., Govindharajulu, J. P., Hollingshead, M., Anderson, L. W., Polley, E., Rubinstein, L., Srivastava, A., Wilsker, D., et al. (2017) · Cancer Research

Computational Drug Discovery MethodsCancer Cells and Metastasis

Cited by 359

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology

Abaan, O. D., Polley, E. C., Davis, S. R., Zhu, Y. J., Bilke, S., Walker, R. L., Pineda, M., Gindin, Y., Jiang, Y., Reinhold, W. C., et al. (2013) · Cancer Research

Cancer Genomics and DiagnosticsGenomics and Rare Diseases

Cited by 288

Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo

Gaur, A. B., Holbeck, S. L., Colburn, N. H., & Israel, M. A. (2011) · Neuro-Oncology

MicroRNA in disease regulationCancer-related molecular mechanisms research

Cited by 180

Two CD95 tumor classes with different sensitivities to antitumor drugs

Algeciras-Schimnich, A., Pietras, E. M., Barnhart, B. C., Legembre, P., Vijayan, S., Holbeck, S. L., & Peter, M. E. (2003) · Proceedings of the National Academy of Sciences

Cell death mechanisms and regulationCancer-related Molecular Pathways

Cited by 118

HLA class I and II genotype of the NCI-60 cell lines

Adams, S., Robbins, F.-M., Chen, D., Wagage, D., Holbeck, S. L., Morse, H. C., Stroncek, D., & Marincola, F. M. (2005) · Journal of Translational Medicine

Immunotherapy and Immune Responsesvaccines and immunoinformatics approaches

Cited by 68